|Mr. Michael S. Weiss||Exec. Chairman, CEO & Pres||827,54k||N/A||1966|
|Mr. Sean A. Power CPA, CPA||CFO, Corp. Sec. & Treasurer||470,56k||N/A||1982|
|Dr. Owen A. O'Connor||Chief Scientific Officer||N/A||N/A||N/A|
|Jenna Bosco||VP of Investor Relations & Sr. VP of Corp. Communications||N/A||N/A||N/A|
|Mr. Adam Waldman||Chief Commercial Officer||N/A||N/A||N/A|
TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and multiple sclerosis (MS). The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. It also develops Ublituximab, a novel anti-CD20 monoclonal antibody, which is in Phase III pivotal study for the treatment of CLL and MS; Umbralisib, a dual PI3K delta and CK1 epsilon inhibitor, which is in Phase III pivotal study for the treatment of CLL, and Phase 2b pivotal study for the treatment of marginal zone lymphoma and follicular lymphoma. In addition, the company develops TG-1501, an anti-PD-L1 monoclonal antibody, which is in Phase I pivotal study for the treatment of B-cell cancers; TG-1701, an oral Bruton's Tyrosine Kinase, which is in Phase I pivotal study for the treatment of B-cell cancers; and TG-1801, an anti-CD47/CD19 bispecific antibody that is in Phase I pivotal study for the treatment of B-cell cancers. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
TG Therapeutics, Inc.s ISS Governance QualityScore, Stand 6. Oktober 2020, lautet 10. Die grundlegenden Scores sind Audit: 2, Vorstand: 10, Shareholderrechte: 4, Kompensation: 10.